-

05:02:01 PM

PRLD Stock News

PRLD - Prelude Therapeutics Inc

11/14/22 8:00 AM

Nasdaq : PRLD

earnings

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor) Company to reprioritize clinical pipeline and discontinue PRMT5 program for internal development Strong cash, cash equivalents and marketable securities of $224.0

RHEA-AI

neutral

10/18/22 8:00 AM

Nasdaq : PRLD

Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug

RHEA-AI

neutral

09/06/22 8:00 AM

Nasdaq : PRLD

conferences

Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences

Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be participating in two healthcare investment conferences next week in New York City. On Monday,

RHEA-AI

neutral

08/09/22 8:00 AM

Nasdaq : PRLD

earnings

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Prelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Administration (FDA) Clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 are on track for the second half of 2022

RHEA-AI

neutral

05/10/22 8:00 AM

Nasdaq : PRLD

earnings

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024 WILMINGTON, Del., May 10, 2022

RHEA-AI

positive

03/16/22 7:30 AM

Nasdaq : PRLD

earnings

Prelude Therapeutics Reports Full Year 2021 Financial Results

Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients Objectives for 2022: Focused on demonstrating proof-of-concept clinical data for lead pipeline compounds and

RHEA-AI

positive

03/11/22 8:00 AM

Nasdaq : PRLD

conferences

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the Barclays 2022 Global Healthcare Conference in

RHEA-AI

neutral

03/09/22 8:05 AM

Nasdaq : PRLD

clinical trial

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

Announces strategic prioritization within lead programs targeting PRMT5 and MCL1 Describes new pipeline candidate, PRT3645, a highly brain penetrant CDK4/6 inhibitor; IND submission planned mid-2022 Advances PRT2527, a highly selective CDK9 inhibitor, with the goal of establishing a recommended

RHEA-AI

positive

03/09/22 8:00 AM

Nasdaq : PRLD

Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

Prelude Therapeutics Incorporated (Nasdaq: PRLD) a clinical-stage precision oncology company, today announced that Jane Huang, M.D., has been appointed to the newly created position of President and Chief Medical Officer, effective on April 4,

RHEA-AI

very positive

02/11/22 7:00 AM

Nasdaq : PRLD

conferences

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Prelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday,

RHEA-AI

neutral

Prev 1 2 3 4 Next

PRLD Data

IndustryPharmaceutical Preparation Manufacturing
Websitepreludetx.com
Security namePrelude Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees122
Tags
- Health Technology
- Biotechnology

About Prelude Therapeutics Inc

prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.